ALLYSON MERCER: Open Payments
NPI 1154000156 · CYPRESS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$759 in 45 payments from 12 companies in 2025. Trend: 2023 $348 · 2024 $1,026 · 2025 $759
Food & beverage: $751Education: $8
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $314 |
| Supernus Pharmaceuticals, Inc. | 11 | $129 |
| Otsuka America Pharmaceutical, Inc. | 5 | $74 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $49 |
| Vanda Pharmaceuticals Inc. | 2 | $48 |
| Tempus AI, Inc | 2 | $40 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Janssen Pharmaceuticals, Inc | 1 | $18 |
| Alkermes, Inc. | 1 | $18 |
| Neurocrine BioSciences, Inc. | 1 | $15 |
Products named: VRAYLAR, Qelbree, REXULTI, CAPLYTA, FANAPT, TEMPUS PIXEL, Auvelity, SPRAVATO.
Industry payments across TX — which companies pay providers there.
